State Insurance Legislators Eye COVID-19 Benefits Snarls
A general session will feature one insurer group rep and two pharmaceutical industry speakers.
State insurance legislators could hear more from the sellers than the buyers when they take up COVID-19 testing, treatment and vaccination issues.
The National Council of Insurance Legislators (NCOIL) has scheduled a health general session on COVID-19 issues for Sept. 25, during an upcoming meeting.
Resources
- Links to NCOIL meeting resources, including the “30-day meeting materials” packet, are available here.
- An earlier article about NCOIL is available here.
NCOIL hopes to start a three-day, in-person meeting Sept. 24, in Alexandria, Virginia.
The preliminary agenda for the health general session lists Rep. Tom Oliverson, a Republican anesthesiologist who represents part of Houston in the Texas House, as the session moderator.
The agenda lists Dave Hering, a regional vice president with Pfizer Vaccines, as one of the speakers, and Sharon Lamberton, a deputy vice president with the Pharmaceutical Research and Manufacturers of America (PhRMA), as another speaker.
The third speaker on the agenda is listed as a representative from America’s Health Insurance Plans.
The agenda does not list any agents, consumers, or representatives from consumer or patient advocacy groups as speakers.
The agenda for NCOIL’s Life Insurance and Financial Planning Committee session reflects how much COVID-19 has affected property and casualty (P&C) lines, such as business interruption insurance, and how little it has affected life, health and annuity issuers, by giving one session the title, “COVID-19 and the Insurance Industry: Not Just a P&C issue.”
Kweilin Ellingrud of McKinsey & Company is listed as the speaker for that committee’s COVID-19 presentation.
— Read 50 States of New Total Death Ratio Data, on ThinkAdvisor.
— Connect with ThinkAdvisor Life/Health on Facebook, LinkedIn and Twitter.